Research programme: corticotropin-releasing factor receptor 1 antagonists - Bristol-Myers Squibb

Drug Profile

Research programme: corticotropin-releasing factor receptor 1 antagonists - Bristol-Myers Squibb

Alternative Names: BMS-764459; CRF1 antagonist

Latest Information Update: 02 Sep 2010

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Ketones; Pyrazines
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Anxiety disorders; Major depressive disorder

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from preclinical studies in anxiety presented at the 240th American Chemical Society National Meeting (240th-ACS-2010) .
  • 30 Aug 2009 Pharmacokinetics and adverse data from a preclincal trial in Depression and Anxiety presented at the 238th Mational Meeting of the American Chemical Society (ACS-2009)
  • 30 Aug 2009 Preclinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top